Literature DB >> 19388361

The modulation of aquaporin-4 by using PKC-activator (phorbol myristate acetate) and V1a receptor antagonist (SR49059) following middle cerebral artery occlusion/reperfusion in the rat.

Kenji Okuno1, Keisuke Taya, Christina R Marmarou, Pinar Ozisik, Giovanna Fazzina, Andrea Kleindienst, Salih Gulsen, Anthony Marmarou.   

Abstract

BACKGROUND: We have pursued the concept that traumatic brain edema is predominantly cellular and that water entry is modulated in part by aquaporins. Aquaporin-4 (AQP4) has been shown to play a significant role in cellular edema formation. Phorbol myristate acetate (PMA) is a potent PKC activator; purportedly involved in modulation of AQP4 activity. Alternatively, AQP4 may be regulated by arginine-vasopressin. Administration of the vasopressin antagonist (SR49059) reduced brain water content and sodium shift following MCAo. To investigate if edema formation is affected by the reduction of AQP4 expression, we utilized PMA and SR49059 following middle cerebral artery occlusion model (MCAo), and measured AQP4 expression by Western-Blot (WB) techniques.
METHODS: Male Sprague Dawley rats were randomly assigned to sham (n=4) or MCAo groups (vehicle, PMA or SR49059 infusion; n=6 each). Each solution was infused for 5 hours, starting 1 hour before injury. After a two-hour period of ischemia and two-hour reperfusion, animals were sacrificed and brain regions of interest were processed by WB to quantify the effect of treatment on AQP4 expression.
RESULTS: These studies demonstrate that MCAo results in a significant up-regulation of AQP4 on the ischemic zone when compared to the contralateral un-injured hemisphere (p < 0.05) and that PMA and SR49059 treatment significantly down-regulated AQP4 expression compared to the vehicle group (p < 0.05).
CONCLUSIONS: These studies support the hypotheses that PMA and SR49059 may be useful in reducing cerebral water accumulation by modulating AQP4 expression and that pharmacological manipulation of AQP4 may emerge as a viable strategy for the reduction of fulminating edema following ischemic injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19388361     DOI: 10.1007/978-3-211-85578-2_84

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  16 in total

1.  Morphine, but not ketamine, decreases the ratio of Th1/Th2 in CD4-positive cells through T-bet and GATA3.

Authors:  Mei Gao; Jie Sun; Wenjie Jin; Yanning Qian
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

2.  Ghrelin prevents disruption of the blood-brain barrier after traumatic brain injury.

Authors:  Nicole E Lopez; Michael J Krzyzaniak; Chelsea Blow; James Putnam; Yan Ortiz-Pomales; Ann-Marie Hageny; Brian Eliceiri; Raul Coimbra; Vishal Bansal
Journal:  J Neurotrauma       Date:  2011-10-26       Impact factor: 5.269

Review 3.  Regulation and Function of AQP4 in the Central Nervous System.

Authors:  Mette Assentoft; Brian Roland Larsen; Nanna MacAulay
Journal:  Neurochem Res       Date:  2015-01-29       Impact factor: 3.996

4.  Real-time monitoring of changes in brain extracellular sodium and potassium concentrations and intracranial pressure after selective vasopressin-1a receptor inhibition following focal traumatic brain injury in rats.

Authors:  Aristotelis S Filippidis; Xiuyin Liang; Weili Wang; Shanaaz Parveen; Clive M Baumgarten; Christina R Marmarou
Journal:  J Neurotrauma       Date:  2014-05-28       Impact factor: 5.269

5.  Arginine-vasopressin V1a receptor inhibition improves neurologic outcomes following an intracerebral hemorrhagic brain injury.

Authors:  Anatol Manaenko; Nancy Fathali; Nikan H Khatibi; Tim Lekic; Yu Hasegawa; Robert Martin; Jiping Tang; John H Zhang
Journal:  Neurochem Int       Date:  2011-01-20       Impact factor: 3.921

6.  Effects of estradiol on ischemic factor-induced astrocyte swelling and AQP4 protein abundance.

Authors:  Jennifer M Rutkowsky; Breanna K Wallace; Phyllis M Wise; Martha E O'Donnell
Journal:  Am J Physiol Cell Physiol       Date:  2011-04-06       Impact factor: 4.249

7.  Selective vasopressin-1a receptor antagonist prevents brain edema, reduces astrocytic cell swelling and GFAP, V1aR and AQP4 expression after focal traumatic brain injury.

Authors:  Christina R Marmarou; Xiuyin Liang; Naqeeb H Abidi; Shanaz Parveen; Keisuke Taya; Scott C Henderson; Harold F Young; Aristotelis S Filippidis; Clive M Baumgarten
Journal:  Brain Res       Date:  2014-06-13       Impact factor: 3.252

8.  Vasopressin V1a Receptors Regulate Cerebral Aquaporin 1 after Traumatic Brain Injury.

Authors:  Katrin Rauen; Viorela Pop; Raimund Trabold; Jerome Badaut; Nikolaus Plesnila
Journal:  J Neurotrauma       Date:  2019-12-04       Impact factor: 5.269

9.  Conivaptan, a Selective Arginine Vasopressin V1a and V2 Receptor Antagonist Attenuates Global Cerebral Edema Following Experimental Cardiac Arrest via Perivascular Pool of Aquaporin-4.

Authors:  Shin Nakayama; Mahmood Amiry-Moghaddam; Ole Petter Ottersen; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2016-04       Impact factor: 3.210

10.  Arginine-vasopressin V1 but not V2 receptor antagonism modulates infarct volume, brain water content, and aquaporin-4 expression following experimental stroke.

Authors:  Xiaoqin Liu; Shin Nakayama; Mahmood Amiry-Moghaddam; Ole Petter Ottersen; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2010-02       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.